Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

10.8%

4 terminated/withdrawn out of 37 trials

Success Rate

89.2%

+2.7% vs industry average

Late-Stage Pipeline

11%

4 trials in Phase 3/4

Results Transparency

18%

6 of 33 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

20(54.1%)

Phase 1

10(27.0%)

N/A

3(8.1%)

Phase 3

3(8.1%)

Phase 4

1(2.7%)

37Total

Phase 2(20)

Phase 1(10)

N/A(3)

Phase 3(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials

NCT01116622Phase 1Completed

Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

Role: collaborator

NCT04629976Phase 1Completed

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Role: collaborator

NCT04627831Phase 2Withdrawn

Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

Role: lead

NCT04309526Phase 1Completed

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

Role: collaborator

NCT03869983Not ApplicableCompleted

Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection

Role: collaborator

NCT00153842Phase 1Terminated

A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer

Role: collaborator

NCT00125359Phase 2Completed

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Role: collaborator

NCT00125372Not ApplicableCompleted

Study of Tarceva and Targretin in Stage I-II Lung Cancer

Role: collaborator

NCT01128959Phase 3Completed

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

Role: collaborator

NCT02851849Phase 2Completed

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Role: lead

NCT02672839Phase 1Completed

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Role: lead

NCT02250222Phase 1Completed

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

Role: lead

NCT01919684Phase 1Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT00003752Phase 2Completed

Bexarotene in Treating Patients With Metastatic Breast Cancer

Role: lead

NCT00006345Phase 2Completed

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Role: lead

NCT00322296Phase 2Terminated

Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

Role: collaborator

NCT00940953Phase 2Completed

Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis

Role: lead

NCT00938613Phase 2Completed

Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR

Role: lead

NCT00063076Phase 2Completed

Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata

Role: collaborator

NCT00623324Phase 2Completed

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

Role: lead